Loading briefing details...
News Digest
By: PointLine Media Research & Editorial Team
Sector:Business,Education,Industry,Lifestyle,Technology
November 12, 2026
Resilient Performance Group, a commercial advisory firm founded by Brian Baldari, has introduced a formal practice focused on addressing the "Landing Gap" in international biotechnology licensing. This term describes the commercial exposure that occurs when pharmaceutical assets developed under one regulatory and payer system are transferred to a new market, such as the United States. The firm aims to assist organizations in reconciling differences in development standards and market expectations during the transition of early-stage assets across international borders.
The rapid increase in cross-border pharmaceutical licensing, particularly involving early-stage assets from China, has highlighted significant challenges in commercial strategy. Industry data indicates that the value of such agreements reached $137.7 billion by 2025, with a substantial portion of these transactions involving preclinical or Phase 1 candidates. The primary concern is that current due diligence processes often focus heavily on clinical science while neglecting the downstream commercial requirements necessary for successful market entry in regions like the United States. This oversight can lead to mismatches between the development program’s design and the specific needs of US regulatory and reimbursement systems.
By formalizing its Cross-Border Commercial Readiness practice, Resilient Performance Group addresses the potential financial and strategic risks associated with these disparities. As companies continue to acquire assets from diverse regulatory environments, the ability to align clinical data with local market access and reimbursement frameworks becomes a critical factor for long-term viability. The shift toward embedded commercial leadership suggests that firms are increasingly looking for external support to manage these complexities throughout the development lifecycle. This trend reflects a broader industry need for comprehensive planning that accounts for the distinct differences in global healthcare systems, ensuring that clinical progress translates effectively into viable, accessible products for patients in new markets.